Asabys Partners Leads a €5.5 Million Round in XRHealth

Asabys Partners leads a new investment round. The venture capital manager specialized in life sciences has led a round of $6 million (€5.5 million) in the American company XRHealth, which has developed a digital healthcare platform, according to expansion.

Nova Prime Fund, an investment vehicle from the Korean consumer electronics giant LG and the North American manager Clearbrook, has also participated in the round , thus entering into the capital of XRHealth. In addition, investors who were already in the company, such as Caixa Capital Risc , have taken part in the operation .

The injection will allow XRHealth to boost its AI-based healthcare platform to treat patients with mental health conditions and support integration with the business, technology and team of Amelia Virtual Care , with whom it merged in September 2023

XRHealth founder and CEO Eran Orr has noted that the funding is intended to support the growth of the platform to make it more accessible no matter where it is.

Read more about Asabys Partners and XRHealth and find other important business news from around the world with our companion app. The Born2Invest mobile app keeps its readers up to date with the most important market updates.

Asabys Partners and XRHealth seek to boost healthcare based on artificial intelligence

Asabys Partners is a venture capital firm specialized in the healthcare sector, founded in 2018 by Josep Lluis Sanfeliu and Clara Campàs, owned by Alantra and with the support of Banc Sabadell as anchor investor. With nearly €217 million in assets under management and fifteen companies in its portfolio, Asabys invests in highly innovative and disruptive companies that cover unmet medical needs in the biopharmaceutical and health technology sectors.

For its part, XRHealth has offices in the Catalan capital and Sydney, as well as an Innovation and Development center in Tel Aviv (Israel), and has sixty employees. The American company offers a comprehensive therapeutic care solution that allows patients to receive treatment from home through augmented reality. Among the main diseases that the company treats are Parkinson’s, multiple sclerosis, stroke rehabilitation and fibromyalgia.

__

(Featured image by Maxim Hopman via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us